hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
hydrochlorothiazide
RxCUI: 403853
What the CMS Formulary Data Shows for hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
Per the CMS 2026 Part D formulary file, hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet (RxNorm concept RXCUI 403853, generic name hydrochlorothiazide) appears on 325 distinct formulary files spanning 4,913 Medicare Part D plan offerings - 97% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.4.
Real-world access to hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 56% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,902,174 Part D beneficiaries filled hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $98,660,150 and an average per-beneficiary annual cost of $20.13. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 325
- Plans covering
- 4,913
- Coverage rate
- 97%
- Tier range
- Tier 1 – Tier 6
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 56% of formularies
2023 Medicare Spending
- Beneficiaries
- 4,902,174
- Total spending
- $98,660,150
- Avg per beneficiary
- $20.13
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet covered by Medicare Part D?
Yes, hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet is covered by 4,913 Medicare Part D plans (97% of all Part D formularies).
What tier is hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet on Medicare Part D plans?
hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet averages Tier 2.4 across Part D plans, ranging from Tier 1 to Tier 6.
Does hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet. Step therapy: 0%. Quantity limits: 56%.
How much does Medicare spend on hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet?
In 2023, total Medicare Part D spending on hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet was $98,660,150, covering 4,902,174 beneficiaries. The average spend per beneficiary was $20.13.
Read our methodology - how this data is sourced, computed, and verified.